A staff of the Beijing Hotgen Biotech Co., Ltd, a bio-pharmaceutical enterprise in Daxing [Photo by Gong Xing and Wang Yan]

Beijing Hotgen Biotech Co., Ltd, a bio-pharmaceutical enterprise in Daxing, has enacted a slew of measures to tackle challenges brought by the outbreak of the novel coronavirus pneumonia, a disease also named by WHO as COVID-19.

Though the coronavirus outbreak has affected many enterprises and caused unexpected difficulties for businesses, Hotgen Biotech has guaranteed its employees that the company would not cut pay or lay off employees with the resumption of production.

In the fight against the COVID-19 the company made utmost efforts to research the virus even during Spring Festival.

The staff at the laboratory of the Beijing Hotgen Biotech Co., Ltd, a bio-pharmaceutical enterprise in Daxing [Photo by Gong Xing and Wang Yan]

The laboratory of the company started research and development on Jan 15 and completed R&D of a nucleic acid reagent on Jan 20. It began conducting research of the expression of gene recombinant protein on Jan 21 and an immune reagent  on Jan 22. Hotgen Biotech successfully developed an immune fast reagent and enzyme immunity reagent on Jan 30.

The staff of the Beijing Hotgen Biotech Co., Ltd, a bio-pharmaceutical enterprise in Daxing [Photo by Gong Xing and Wang Yan]

“Thanks to the measures and policies of the Chinese government, our company is confident in winning the battle against the epidemic caused by the novel coronavirus. I am sure that the government will be a strong supporter of enterprises in the face of the epidemic,” said an employee at the company.